Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Abstract: The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

Abstract: The present invention relates to a viral strain derived from the human metapneumovirus (hMPV) strain having a genome sequence represented by sequence SEQ ID NO. 1, wherein said genome sequence comprises the following genetic modifications: (i) inactivation of the endogenous gene coding for the SH protein and/or for the G protein, and (ii) presence of an exogenous nucleotide sequence coding for at least one extracellular domain of the F protein of the human respiratory syncytial virus (hRSV), said domain being wild-type or mutated.

Abstract: The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.

Abstract: Derivatives of 10S, 17S-diHIDA (protectin DX, PDX) and medicinal uses thereof are disclosed. These derivatives are specialized pro-resolving mediators (SPRMs). In specific embodiments, said derivatives are used in to prevent or treat viral infections (including influenza and coronavirus infections), insulin resistance, diabetes, and inflammatory disorders.

Abstract: The invention relates to a combination of Diltiazem and at least one viral polymerase inhibitor compound selected from among Baloxavir marboxil, Pimodivir, RO-7 and CC-42344. The invention relates in particular to the therapeutic use of said combination in the prevention and/or treatment of a viral infection, in particular of the respiratory and/or intestinal tract of a human or animal body.

Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.

Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. The composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Abstract: The present invention relates to the use of the immortalised cell line ECACC 09070703, deposited on 7 Jul. 2009 at the European Collection of Authenticated Cell Cultures (ECACC, Salisbury, UK) under the number 09070703, for the production of a viral vaccine constituted of an attenuated strain derived from a human metapneumovirus.

Abstract: The present invention relates to an attenuated virus strain derived from a human metapneumovirus strain comprising the genome sequence represented by sequence SEQ ID NO. 1, said attenuated strain comprising one or more genetic modifications of said sequence SEQ ID NO. 1 attenuating the virulence of said strain.

Abstract: The present invention relates to diltiazem for use as an agent for activating the expression of at least one gene encoding a type III interferon, in the prevention and/or treatment of infections by at least one pathogenic microorganism of the epithelia of the respiratory and/or intestinal tracts.

Abstract: The present invention relates to a pharmaceutical or veterinary composition for the use thereof in preventing and/or treating infection by the influenza viruses. Said composition is characterized in that it contains, in an appropriate pharmaceutical carrier, at least one compound selected from among Etilefrine and Diltiazem.

Abstract: The present invention is concerned with the use of Protease-Activated Receptor-1 (PAR1) inhibitors for preventing or treating a Paramyxoviridae infection in a subject. Described herein are methods, compounds and pharmaceutical compositions useful in addressing such infections, and more particularly infections from human respiratory syncytial virus (hRSV) and human metapneumovirus (hMPV).

Abstract: 3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were particularly active against HSV-1 and HSV-2 strains and one compound (No 3) inhibited specifically cytomegalovirus (CMV) strains (overall hit rate of 25%). Some of the tested compounds inhibited wild-type viruses and strains resistant to current antiviral agents. New chemical entity derivatives of compound 2 with binding potential to the DNA polymerase retained an excellent activity against HSV-1, HSV-2 and VZV like the parental compound, as well against strains resistant to current antiviral agents. These non-nucleosidic herpesvirus DNA polymerase inhibitors with in vitro activity against drug-resistant clinical isolates warrant further pre-clinical studies.

Abstract: 3D protein modeling and virtual screening of commercially-available compounds were performed to identify new inhibitors of the herpesvirus DNA polymerase, a key enzyme in the viral replication cycle. Two compounds (Nos 2 and 9) were particularly active against HSV-1 and HSV-2 strains and one compound (No 3) inhibited specifically cytomegalovirus (CMV) strains (overall hit rate of 25%). Some of the tested compounds inhibited wild-type viruses and strains resistant to current antiviral agents. New chemical entity derivatives of compound 2 with binding potential to the DNA polymerase retained an excellent activity against HSV-1, HSV-2 and VZV like the parental compound, as well against strains resistant to current antiviral agents. These non-nucleosidic herpesvirus DNA polymerase inhibitors with in vitro activity against drug-resistant clinical isolates warrant further pre-clinical studies.

Abstract: A method of detecting the presence of a plurality of respiratory viruses using a multiplexed diagnostic assay is disclosed. The method provides a plurality of oligonucleotides that each is specific for a specific respiratory virus. A multiplex PCR is run using the oligonucleotides, which produces double-stranded products. The method also provides a plurality of extension oligonucleotides that each is specific for a specific double-stranded product. Each extension oligonucleotide also has a distinct second portion having a unique sequence. A primer extension reaction is run using the extension oligonucleotides, which produces single-stranded products. The single-stranded products are hybridized to a solid carrier.

Abstract: The present invention relates to methods of detection, as well as assays, reagents and kits for the specific detection of 15 clinically important respiratory viruses including influenza A and B viruses, human respiratory syncytial viruses, human metapneumoviruses, human enteroviruses, all serotypes of rhinoviruses, 7 serotypes of adenoviruses, parainfluenza viruses types 1, 2, 3, and 4, as well as coronaviruses NL, 229E, OC43, and SARS-CoV. The present invention allows for the detection of each of these respiratory viruses in a single assay.

Abstract: The present invention relates to new methods and nucleic acid sequences for the detection and quantification of human metapneumovirus.